REC No	IRAS No	Name of Trial	First Patient Recruited?	Date of First Patient Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Patient Recruited	Duration between Date Site Selected and First Patient Recruited	Benchmark Met	Date Study Initiated	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	A - Permissions delayed/ denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Reasons for delay correspond to:
16/LO/1628	199315	The ACL SNNAP Trial: ACL Surgery Necessity in Non Acute Patients. Comparison of the clinical and cost effectiveness of two management strategies for non-acute Anterior Cruciate Ligament (ACL) injury: Rehabilitation versus surgical Reconstruction.	Yes	08/12/2017	174	44	218	No		04/05/2017	04/05/2017	16/11/2016	03/10/2017	25/10/2017	Please Select...	25/10/2017				Y		Y					Sponsor
17/SC/0142	215503	Evaluating the clinical and cost-effectiveness of permissive hypotension in critically ill patients aged 65 years or over with vasodilatory hypotension	Yes	18/10/2017	172	19	191	No		10/04/2017	10/04/2017	24/04/2017	08/08/2017	29/09/2017	Please Select...	29/09/2017	Y							Y			Sponsor
16/EE/0514	207302	Randomized, Double-Blind Phase 2/3 Study in Subjects with Malignant Pleural Mesothelioma with Low Argininosuccinate Synthetase 1 Expression to Assess ADI-PEG 20 with Pemetrexed and Cisplatin (ATOMIC-Meso Phase 2/3 Study)	Yes	15/11/2017	167	21	188	No		20/01/2017	11/05/2017	28/02/2017	18/10/2017	25/10/2017	Please Select...	25/10/2017				Y							Sponsor
16/LO/1416	209276	Lower Protein Intake and Long-term Risk of Obesity and Cardiovascular Disease; A Multi-centred Randomised Controlled Trial	Yes	07/08/2017	63	116	179	No		13/12/2016	09/02/2017	16/11/2016	10/04/2017	13/04/2017	Please Select...	13/04/2017								Y			Neither
16/WS/0093	200488	(FAK-PD1) A Phase I/IIA study to assess safety, tolerability and preliminary activity of the combination of FAK (defactinib) and PD-1 (pembrolizumab) inhibition in patients with advanced solid malignancies	Yes	04/10/2017	116	44	160	No		13/04/2017	27/04/2017	25/04/2017	26/07/2017	21/08/2017	Please Select...	21/08/2017				Y			Y				Sponsor
16/EM/0500	213455	Treatment of heart failure using indapamide : a pilot study of its effect on plasma FGF23	Yes	15/06/2017	55	99	154	No		13/10/2016	12/01/2017	14/02/2017	08/03/2017	08/03/2017	Please Select...	08/03/2017				Y			Y				Sponsor
17/EM/0003	210798	Patient Input Monitoring of Pain in the Emergency Room: Novel Electronic Log (PIMPERNEL):feasibility study. A randomised controlled trial of an electronic pain score display in the emergency department.	Yes	06/07/2017	88	28	116	No		12/03/2017	12/03/2017	24/02/2017	12/03/2017	08/06/2017	Please Select...	08/06/2017	Y										Neither
17/YH/0120	208838	A pragmatic multi-centre randomised controlled non inferiority, cost effectiveness trial comparing injections of collagenase into the cord to surgical correction in the treatment of moderate Dupuytren?s Contracture in adult patients	Yes	31/07/2017	76	40	116	No		21/02/2017	06/04/2017	25/05/2017	21/06/2017	21/06/2017	Please Select...	21/06/2017				Y			Y				Sponsor
17/EM/0059	221778	A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with reduced Ejection Fraction(HFrEF).	Yes	17/10/2017	5	110	115	No		28/10/2016	24/06/2017	09/06/2017	21/06/2017	29/06/2017	Please Select...	29/06/2017				Y							Sponsor
17/LO/0915	221191	PEMAGS: A Prospective fEasibility study of Minimal Access Gynaecological Surgery	Yes	28/08/2017	89	13	102	No		05/05/2017	18/05/2017	20/07/2017	15/08/2017	15/08/2017	Please Select...	15/08/2017	Y							Y			Neither
17/LO/0782	227047	Placebo-Controlled Proof of Concept Study to Investigate ANB020 Activity in Adult Patients with Severe Eosinophilic Asthma	Yes	21/11/2017	29	70	99	No		15/02/2017	14/08/2017	23/06/2017	14/08/2017	12/09/2017	Please Select...	12/09/2017							Y				Neither
16/WS/0197	186191	ATLANTIS: An adaptive multi-arm phase II trial of maintenance targeted therapy after chemotherapy in metastatic urothelial cancer	Yes	03/07/2017	23	74	97	No		09/12/2016	28/03/2017	01/02/2017	06/04/2017	20/04/2017	Please Select...	20/04/2017							Y				Neither
17/SC/0242	222650	Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Intravenous FDY-5301 in Acute Myocardial Infarction (Protocol No. FDY-5301-201)	Yes	12/12/2017	11	85	96	No		13/03/2017	07/09/2017	06/09/2017	07/09/2017	18/09/2017	Please Select...	18/09/2017							Y				Neither

REC No	IRAS No	Name of Trial	First Patient Recruited?	Date of First Patient Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Patient Recruited	Duration between Date Site Selected and First Patient Recruited	Benchmark Met	Date Study Initiated	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	A - Permissions delayed/ denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Reasons for delay correspond to:
16/NE/0384	209045	A multi-centre, randomised, double-blind, active-controlled, parallel-group Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to ramipril on morbidity and mortality in high risk patients following an acute myocardial infarction.	Yes	24/04/2017	13	76	89	No		19/07/2016	25/01/2017	05/01/2017	30/01/2017	07/02/2017	Please Select...	07/02/2017							Y				Neither
17/LO/0023	215490	MUK nine b: OPTIMUM. A phase II study evaluating optimised combination of biological therapy in newly diagnosed high risk multiple myeloma and plasma cell leukaemia.	Yes	20/11/2017	13	76	89	No		13/03/2017	23/08/2017	30/03/2017	23/08/2017	05/09/2017	Please Select...	06/09/2017							Y				Neither
16/WM/0505	211350	Promoting physical activity through group self-management support for those with multi-morbidity: a randomised clinical trial	Yes	14/06/2017	17	68	85	No		01/12/2016	21/03/2017	21/03/2017	01/12/2016	07/04/2017	Please Select...	07/04/2017							Y				Neither
16/NS/0106	212541	Reducing Asthma Attacks in Children using Exhaled Nitric Oxide as a biomarker to inform treatment strategy	Yes	14/08/2017	21	46	67	Yes		19/05/2017	08/06/2017	04/04/2017	05/07/2017	29/06/2017	Please Select...	29/06/2017											
16/EE/0463	214371	An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (ABC) with no prior hormonal therapy for advanced disease	Yes	06/04/2017	45	20	65	Yes		15/11/2016	31/01/2017	30/01/2017	07/03/2017	17/03/2017	Please Select...	17/03/2017											
17/SC/0016	218645	A Phase III, Randomized, Open Label Trial of Nivolumab in combination with Ipilimumab versus Pemetrexed with Cisplatin or Carboplatin as First Line Therapy in unresectable Pleural Mesothelioma	Yes	14/06/2017	18	47	65	Yes		10/03/2017	10/04/2017	16/03/2017	21/04/2017	28/04/2017	Please Select...	28/04/2017											
17/LO/0095	216048	A tailored, cognitive behavioural approach intervention for mild to moderate anxiety and/or depression in people with chronic obstructive pulmonary disease (COPD): A randomised controlled trial	Yes	14/06/2017	36	27	63	Yes		09/03/2017	12/04/2017	08/03/2017	26/04/2016	18/05/2017	Please Select...	31/05/2017											
17/WM/0011	219130	A Phase II, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in IgA Nephropathy	Yes	08/08/2017	1	61	62	Yes		30/03/2016	07/06/2017	19/04/2017	17/05/2017	08/06/2017	Please Select...	08/06/2017											
17/EM/0156	220947	A Randomised Controlled Trial to Investigate the Use of High Frequency Airway Oscillations as Training to Improve Dyspnoea in COPD	Yes	27/06/2017	49	13	62	Yes		10/02/2017	26/04/2017	12/06/2017	17/03/2017	14/06/2017	Please Select...	14/06/2017											
17/NE/0115	218417	Phase II study of Pirfenidone vs placebo in patients with fibrotic ILD that cannot be classified with moderate or high confidence into any other category of fibrotic IP by Multidisciplinary Team (MDT) review (?unclassifiable? ILD).	Yes	16/08/2017	3	58	61	Yes		31/05/2017	16/06/2017	26/05/2017	06/06/2017	19/06/2017	Please Select...	19/06/2017											
16/EM/0488	210608	A randomised controlled trial to investigate the effect of a structured education programme on women who have had gestational diabetes and are at risk of developing type 2 diabetes.	Yes	04/05/2017	23	34	57	Yes		03/11/2016	08/03/2017	01/03/2017	31/03/2017	31/03/2017	Please Select...	31/03/2017											

REC No	IRAS No	Name of Trial	First Patient Recruited?	Date of First Patient Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Patient Recruited	Duration between Date Site Selected and First Patient Recruited	Benchmark Met	Date Study Initiated	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	A - Permissions delayed/ denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Reasons for delay correspond to:
17/EM/0055	222279	A Randomized, Double-Blind, Placebo controlled, Parallel Group Study of Patiromer for the Enablement of Spironolactone Use for Blood Pressure Control in Patients with Resistant Hypertension and Chronic Kidney Disease: Evaluation of Safety and Efficacy (AMBER)	Yes	28/07/2017	0	57	57	Yes		29/11/2016	01/06/2017	02/05/2017	01/05/2017	01/06/2017	Please Select...	01/06/2017											
16/SS/0153	211403	Cardiac Magnetic Resonance guided management of mild- moderate Heart Failure	Yes	17/07/2017	8	45	53	Yes		18/07/2016	25/05/2017	25/11/2016	02/03/2017	02/06/2017	Please Select...	02/06/2017											
17/NW/0292	223951	Phase 1b multi-indication study of anetumab ravtansine (BAY 94-9343) in patients with mesothelin expressing advanced or recurrent malignancies	Yes	17/11/2017	15	37	52	Yes		13/06/2017	26/09/2017	27/07/2017	05/10/2017	11/10/2017	Please Select...	11/10/2017											
16/NW/0517	188554	A phase III study to determine the role of ixazomib as an Augmented Conditioning therapy in salvage autologous stem	Yes	13/04/2017	36	15	51	Yes		04/10/2016	21/02/2017	27/10/2016	06/04/2017	29/03/2017	Please Select...	29/03/2017											
17/EM/0019	214674	Establishing normal ranges of microcirculatory function as determined by CytoCam- IDF imaging	Yes	16/03/2017	13	38	51	Yes		20/10/2016	24/01/2017	24/01/2017	25/01/2017	06/02/2017	Please Select...	06/02/2017											
17/WM/0219	224822	A feasibility study considering the use of the STAK Tool in addition to standard physiotherapy compared to standard physiotherapy alone to treat arthrofibrosis patients following total knee replacement.	Yes	02/08/2017	49	2	51	Yes		22/05/2017	12/06/2017	18/07/2017	31/07/2017	31/07/2017	Please Select...	31/07/2017											
17/EE/0022	221514	A PHASE II, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF MOXR0916 IN COMBINATION WITH ATEZOLIZUMAB VERSUS ATEZOLIZUMAB ALONE IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WHO ARE INELIGIBLE FOR CISPLATIN-BASED THERAPY	Yes	22/06/2017	36	14	50	Yes		17/02/2017	03/05/2017	22/02/2017	02/06/2017	08/06/2017	Please Select...	08/06/2017											
17/WS/0071	224151	An International, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Dapagliflozin on the Incidence of the composite of =40% sustained reduction in eGFR, entering ESRD, CV or Renal Death in patients with Albuminuria and Moderate to Severe Renal Impairment (CKD 3-4)	Yes	01/12/2017	24	25	49	Yes		09/02/2017	13/10/2017	22/05/2017	25/10/2017	06/11/2017	Please Select...	06/11/2017											
17/LO/0249	220398	A PHASE III, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH ENZALUTAMIDE VERSUS ENZALUTAMIDE ALONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF AN ANDROGEN SYNTHESIS INHIBITOR AND FAILURE OF, INELIGIBILITY FOR, OR REFUSAL OF A TAXANE REGIMEN	Yes	17/08/2017	12	37	49	Yes		24/01/2017	29/06/2017	28/04/2017	22/06/2017	11/07/2017	Please Select...	11/07/2017											
17/EE/0255	227279	A DOUBLE-BLIND, RANDOMISED, PLACEBO CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF THREE DOSES OF ORVEPITANT IN PATIENTS WITH CHRONIC REFRACTORY COUGH	Yes	16/10/2017	5	42	47	Yes		10/04/2017	30/08/2017	26/07/2017	22/08/2017	04/09/2017	Please Select...	04/09/2017											
16/EE/0372	212494	DETECTION OF METHACHOLINE CHALLENGE INDUCED ASTHMA SYMPTOMS USING A NOVEL DEVICE.	Yes	02/03/2017	21	24	45	Yes		03/10/2016	16/01/2017	22/12/2016	29/09/2016	06/02/2017	Please Select...	06/02/2017											

REC No	IRAS No	Name of Trial	First Patient Recruited?	Date of First Patient Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Patient Recruited	Duration between Date Site Selected and First Patient Recruited	Benchmark Met	Date Study Initiated	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	A - Permissions delayed/ denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Reasons for delay correspond to:
17/EM/0192	223856	Title: A Phase 2, 24-week, Randomized, Double-Blind, Placebo-Controlled, Mulitcenter Study, Followed by a 24-Week Extension, to Evaluate the Efficacy and Safety of CC-90001 in Subjects with Idiopathic Pulmonary Fibrosis	Yes	20/11/2017	14	31	45	Yes		07/02/2017	06/10/2017	14/09/2017	12/07/2017	20/10/2017	Please Select...	20/10/2017											
17/SC/0294	224828	Title: A Phase III Randomised Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) in Combination with Neoadjuvant Anthracycline/Nab-paclitaxel Based Chemotherapy Compared with Placebo and Chemotherapy in Patients with Primary Invasive Triple-Negative Breast Cancer	Yes	02/11/2017	32	10	42	Yes		10/02/2017	21/09/2017	02/08/2017	11/10/2017	23/10/2017	Please Select...	23/10/2017											
15/SW/0194	185459	A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven phase 3 study to investigate the efficacy of finerenone on the progression of deterioration of kidney function in patients with type 2 diabetes mellitus and the clinical diagnosis of advanced diabetic kidney disease in addition to standard of care.	Yes	17/08/2017	0	41	41	Yes		29/03/2017	07/07/2017	17/06/2016	03/07/2017	07/07/2017	Please Select...	07/07/2017											
17/LO/0041	219676	CardioMEMS OUS	Yes	22/11/2017	4	36	40	Yes		23/01/2017	13/10/2017	06/03/2017	17/08/2017	17/10/2017	Please Select...	17/10/2017											
16/LO/2078	213487	An open-label, multicentre, dose-escalation, phase Ia/Ib study to evaluate safety, pharmacokinetics and therapeutic activity of RO6874281, an immunocytokine consisting of interleukin 2 variant (IL-2v) targeting fibroblast activation protein-a (FAP), as a single agent (Part A) or in combination with trastuzumab or cetuximab following pretreatment with obinutuzumab (part B or C)	Yes	14/03/2017	7	32	39	Yes		19/10/2016	03/02/2017	03/02/2017	08/02/2017	10/02/2017	Please Select...	10/02/2017											
17/WS/0184	222904	The effects of an 8-week vegan diet on Trimethylamine-N-Oxide (TMAO) levels and post-challenge glucose levels in individuals with dysglycaemia..	Yes	17/10/2017	26	13	39	Yes		03/08/2017	08/09/2017	08/09/2017	04/10/2017	04/10/2017	Please Select...	04/10/2017											
16/EM/0482	216043	Participant Acceptability of Exercise in Kidney Disease	Yes	15/03/2017	24	13	37	Yes		08/11/2016	06/02/2017	27/01/2017	02/03/2017	02/03/2017	Please Select...	02/03/2017											
16/WM/0472	211270	CheckpOiNt blockade For Inhibition of Relapsed Mesothelioma (CONFIRM): A Phase III Trial to Evaluate the Efficacy of Nivolumab in Relapsed Mesothelioma	Yes	19/04/2017	14	22	36	Yes		01/11/2016	14/03/2017	14/03/2017	20/03/2017	28/03/2017	Please Select...	28/03/2017											
16/LO/1940	213099	AN OPEN LABEL, SINGLE ARM, MULTICENTER, SAFETY STUDY OF ATEZOLIZUMAB IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL OR NON-UROTHELIAL CARCINOMA OF THE URINARY TRACT	Yes	09/02/2017	29	6	35	Yes		17/10/2016	05/01/2017	12/01/2017	30/01/2017	03/02/2017	Please Select...	03/02/2017											
16/WM/0473	213847	Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Advanced Malignancies	Yes	25/04/2017	6	27	33	Yes		12/09/2016	23/03/2017	02/03/2017	23/03/2017	29/03/2017	Please Select...	29/03/2017											
14/WM/0049	145163	An open-label single-arm multicentre non-controlled phase 3a trial investigating safety and efficacy of nonacog beta pegol (N9-GP) in prophylaxis and treatment of bleeding episodes in previously untreated patients with haemophilia B (FIX activity =2%)	Yes	15/12/2017	10	22	32	Yes		28/06/2017	13/11/2017	24/07/2017	13/11/2017	23/11/2017	Please Select...	23/11/2017											

REC No	IRAS No	Name of Trial	First Patient Recruited?	Date of First Patient Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Patient Recruited	Duration between Date Site Selected and First Patient Recruited	Benchmark Met	Date Study Initiated	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	A - Permissions delayed/ denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Reasons for delay correspond to:
15/NW/0416	167060	A randomised phase II trial of Cyclophosphamide and Dexamethasone in combination with Ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and bortezomib	Yes	23/11/2017	10	21	31	Yes		21/07/2017	23/10/2017	15/07/2016	27/10/2017	02/11/2017	Please Select...	02/11/2017											
17/LO/1068	224973	A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL TESTING IPATASERTIB PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE, RELATIVE TO PLACEBO PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE IN ADULT MALE PATIENTS WITH ASYMPTOMATIC OR MILDLY SYMPTOMATIC, PREVIOUSLY UNTREATED, METASTATIC CASTRATE-RESISTANT PROSTATE CANCER	Yes	23/11/2017	7	23	30	Yes		20/04/2017	24/10/2017	27/07/2017	20/10/2017	31/10/2017	Please Select...	30/10/2017											
17/EM/0166	222665	AVAIL-T: A Phase 2a trial of Avelumab, an anti-PDL1 antibody, in relapsed and refractory peripheral T-cell lymphoma (PTCL)	Yes	29/11/2017	6	20	26	Yes		13/04/2017	03/11/2017	30/06/2017	02/11/2017	09/11/2017	Please Select...	09/11/2017											
17/LO/0402	209419	A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) AS ADJUVANT THERAPY IN PATIENTS WITH PD-L1-SELECTED RENAL CELL CARCINOMA AT INTERMEDIATE TO HIGH RISK OF DEVELOPING METASTASIS FOLLOWING NEPHRECTOMY	Yes	06/07/2017	8	16	24	Yes		10/11/2016	12/06/2017	09/06/2017	13/06/2017	20/06/2017	Please Select...	20/06/2017											
17/LO/0504	224298	An open-label, single arm, repeat dose, multi-centre study to evaluate the use of an autoinjector for the subcutaneous administration of mepolizumab in subjects with severe eosinophilic asthma	Yes	07/07/2017	8	15	23	Yes		10/04/2017	14/06/2017	15/05/2017	12/06/2017	22/06/2017	Please Select...	22/06/2017											
15/WM/0268	180518	Randomised, open label study of rituximab/ibrutinib vs rituximab/chemotherapy in older patients with untreated mantle cell lymphoma	Yes	20/07/2017	8	13	21	Yes		17/03/2017	29/06/2017	26/08/2016	26/06/2017	07/07/2017	Please Select...	07/07/2017											
17/EM/0014	219556	Prospective Clinical Investigation for a Randomized, Controlled, Multicenter Non-inferiority Study Comparing Standard Wound Closure Technique with Drains (control) to Standard Wound Closure Techniques with TissuGlu? and No Drains (test) in Mastectomy.	Yes	30/03/2017	11	9	20	Yes		16/01/2017	10/03/2017	10/03/2017	14/03/2017	21/03/2017	Please Select...	21/03/2017											
17/SC/0083	218035	A Prospective, Randomized, Open Label, Multi-center Study of the Safety and Pharmacokinetics of Apixaban versus Vitamin K Antagonist or LMWH in Pediatric Subjects with Congenital or Acquired Heart Disease Requiring Chronic Anticoagulation for Thromboembolism Prevention	Yes	11/09/2017	0	18	18	Yes		10/01/2017	24/08/2017	07/07/2017	18/08/2017	24/08/2017	Please Select...	24/08/2017											
16/WM/0512	218042	A Phase 1, open-label, randomised, repeat dose parallel group study to evaluate the pharmacokinetics, safety and tolerability of ferric maltol at three dosage levels in paediatric subjects (aged 10-17) with iron deficiency (with or without Anaemia)	Yes	28/11/2017	3	12	15	Yes		01/09/2017	13/11/2017	23/02/2017	07/11/2017	16/11/2017	Please Select...	16/11/2017											
16/NS/0094	206213	BioImpedance Spectroscopy to Maintain Renal Output: The BISTRO Trial	Yes	20/11/2017	6	5	11	Yes		15/11/2016	09/11/2017	04/10/2016	03/11/2017	15/11/2017	Please Select...	15/11/2017											

REC No	IRAS No	Name of Trial	First Patient Recruited?	Date of First Patient Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Patient Recruited	Duration between Date Site Selected and First Patient Recruited	Benchmark Met	Date Study Initiated	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	A - Permissions delayed/ denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Reasons for delay correspond to:
15/LO/0638	176799	Paclitaxel assisted balloon Angioplasty of Venous stenosis in haEmodialysis access: The PAVE trial. A multicentre double-blind randomised controlled trial in haemodialysis patients with a stenosis in a native arteriovenous fistula.	Yes	30/11/2017	5	3	8	Yes		23/03/2017	22/11/2017	21/09/2016	27/11/2017	27/11/2017	Please Select...	27/11/2017											
17/EE/0264	228153	POSEIDON - A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non-Small-Cell Lung Cancer (NSCLC)	Yes	21/11/2017	1	7	8	Yes		16/06/2017	13/11/2017	12/09/2017	09/11/2017	14/11/2017	Please Select...	15/11/2017											
12/NE/0345	93752	A Cancer Research UK Phase I Trial of AZD3965, a monocarboxylate transporter 1 inhibitor (MCT1) in patients with advanced cancer	No		3			Within 70 Days		14/12/2016	27/11/2017	07/08/2017	20/11/2017	30/11/2017	Please Select...	30/11/2017											
16/LO/1355	168344	InPACT trial- International Penile Advanced Cancer Trial (International Rare Cancers Initiative study)	No		14			Within 70 Days		16/12/2016	01/12/2017	11/10/2016	15/12/2017	15/12/2017	Please Select...	15/12/2017											
15/EE/0158	168042	Real Time Continuous Glucose Monitoring in Neonatal Intensive Care	No		32			Within 70 Days		06/10/2017	17/11/2017	26/08/2016	21/11/2017	19/12/2017	Please Select...	19/12/2017											
16/LO/0422	198606	A Phase I Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Gemcitabine plus Cisplatin or Gemcitabine Alone in Subjects with Advanced Cancer	No		2			Within 70 Days		26/05/2017	06/12/2017	23/05/2016	15/11/2017	08/12/2017	Please Select...	08/12/2017											
16/LO/0423	198451	A Phase I trial of SRA737 (a CHK1 inhibitor) administered orally in subjects with advanced cancer	No		0			Within 70 Days		01/05/2017	31/10/2017	19/05/2016	11/10/2017	31/10/2017	Please Select...	30/10/2017											
16/LO/1822	212944	A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator Vericiguat in subjects with heart failure and reduced ejection fraction (HFrEF) - VerICiguaT glObal study in subjects with heart failure and Reduced ejectIon frAction (VICTORIA)	No		13			No		15/09/2016	23/02/2017	07/12/2016	07/02/2017	08/03/2017	Please Select...	08/03/2017							Y				Neither
17/NW/0371	216207	A Randomized, Double-Blind, Multicenter, 3 Stage, Efficacy and Safety Study of NI-071 and US-Licensed Remicade? (Infliximab) for the Treatment of Patients with Rheumatoid Arthritis	No		34			No		13/10/2016	15/08/2017	25/07/2017	15/08/2017	18/09/2017	Please Select...	18/09/2017				Y							Sponsor
17/NE/0092	220929	A phase 3 C Difficile vaccine efficacy study - PF-06425090 for prevention of Clostridium difficile infection (CDI)	No		4			No		12/12/2016	03/08/2017	28/03/2017	05/07/2017	07/08/2017	Please Select...	03/08/2017							Y				Neither
17/LO/0065	219950	A phase III randomized, double-blind study comparing the combination of PDR001, dabrafenib and trametinib to the combination of dabrafenib and trametinib as first line therapy in patients with unresectable or metastatic BRAF V600 mutant melanoma with elevated LDH	No		8			No		21/02/2017	26/09/2017	14/02/2017	26/09/2017	04/10/2017	Please Select...	04/10/2017						Y			Y		Neither
17/EE/0361	231209	A 2-treatment epoch, randomized, placebo-controlled, multicenter parallel-group study to assess the safety of QAW039 when added to existing asthma therapy in patients with uncontrolled severe asthma	No		0			Within 70 Days		15/09/2017	01/11/2017	31/10/2017	09/10/2017	01/11/2017	Please Select...	01/11/2017											

REC No	IRAS No	Name of Trial	First Patient Recruited?	Date of First Patient Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Patient Recruited	Duration between Date Site Selected and First Patient Recruited	Benchmark Met	Date Study Initiated	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	A - Permissions delayed/ denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Reasons for delay correspond to:
16/EE/0370	198596	MesoTRAP: A feasibility study comparing video-assisted thoracoscopic partial pleurectomy/decortication with indwelling pleural catheter in patients with trapped lung due to malignant pleural mesothelioma designed to address recruitment and randomisation uncertainties and sample size requirements for a phase III trial.	No		33			No		24/02/2017	23/08/2017	11/01/2017	21/09/2017	25/09/2017	Please Select...	25/09/2017							Y				Neither
17/EM/0063	213979	A Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial of the FLT3 Inhibitor Gilteritinib (ASP2215) Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects with FLT3/ITD AML in First Complete Remission	No		53			No		10/08/2016	10/08/2017	27/04/2017	22/09/2017	02/10/2017	Please Select...	02/10/2017						Y					Neither
16/NE/0279	198051	Risk-stratified sequential Treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for De-novo post-transplant Lymphoproliferative disorder (PTLD)	No		142			No		06/03/2017	03/04/2017	29/09/2016	27/06/2017	23/08/2017	Please Select...	23/08/2017				Y			Y				Sponsor
17/EM/0275	227425	A Multi-center, Double-blind, Randomized, Three-Arm, Parallel-Group, Placebo Controlled Study to Assess the Efficacy and Safety of NTRA-2112 on Intestinal Malabsorption in Preterm Infants	No		40			No		20/07/2017	14/09/2017	13/09/2017	15/10/2017	24/10/2017	Please Select...	04/12/2017							Y				Neither
17/EE/0081	219405	An open label, single arm safety study of OncoSil?, administered to study participants with unresectable locally advanced pancreatic adenocarcinoma, given in combination with FOLFIRINOX or gemcitabine+nab-paclitaxel chemotherapies.	No		9			No		07/04/2017	18/07/2017	08/05/2017	20/07/2017	27/07/2017	Please Select...	27/07/2017							Y				Neither
17/EM/0190	219055	A Phase 3b, Randomized, Active Comparator, Open-label, Multicenter Study to Compare the Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and to Glimepiride as Add-on Therapy to Metformin in Patients with Type 2 Diabetes	No		8			No		01/03/2017	28/09/2017	01/08/2017	03/08/2017	06/10/2017	Please Select...	06/10/2017				Y							Sponsor
17/WS/0072	221444	EDOXABAN VERSUS STANDARD OF CARE AND THEIR EFFECTS ON CLINICAL OUTCOMES IN PATIENTS HAVING UNDERGONE TRANSCATHETER AORTIC VALVE IMPLANTATION ? IN ATRIAL FIBRILLATION	No		18			No		11/05/2017	21/09/2017	06/06/2017	04/10/2017	09/10/2017	Please Select...	09/10/2017				Y	Y		Y				Both
17/EM/0058	221776	A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with preserved Ejection Fraction (HFpEF).	No		5			No		28/10/2016	24/06/2017	05/06/2017	21/06/2017	29/06/2017	Please Select...	29/06/2017							Y				Neither
17/EM/0315	220334	A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease	No		115			No		11/10/2016	08/08/2017	03/11/2017	22/05/2017	01/12/2017	Please Select...	01/12/2017				Y							Sponsor
17/EE/0079	220827	A Randomized, double-blind, placebo-controlled, phase 3 study to evaluate the safety and efficacy of CCX168 in patients with anti-neutrophil cytoplasmic antibody (ANCA)- Associated Vasculitis Treated Concomitantly with Rituximab or Cyclophosphamise/ Azathioprine	No		63			No		28/11/2016	09/05/2017	06/04/2017	05/07/2017	11/07/2017	Please Select...	11/07/2017				Y		Y			Y		Sponsor

REC No	IRAS No	Name of Trial	First Patient Recruited?	Date of First Patient Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Patient Recruited	Duration between Date Site Selected and First Patient Recruited	Benchmark Met	Date Study Initiated	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	A - Permissions delayed/ denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Reasons for delay correspond to:
17/LO/1427	216241	The effects of Calcium Channel Blockers or Angiotensin converting enzyme inhibitor/Angiotensin Receptor Blocker Therapy on Blood Pressure Variability following acute ischaemic Stroke (CAARBS): A Feasibility Trial	No		14			Within 70 Days		01/09/2017	29/11/2017	25/09/2017	22/11/2017	13/12/2017	Please Select...	13/12/2017											
17/EM/0367	231327	A multi-centre, open-label extension, safety study to describe the longterm clinical experience of mepolizumab in participants with hypereosinophilic syndrome (HES) from Study 200622	No		18			Within 70 Days		06/09/2017	16/11/2017	10/11/2017	27/11/2017	04/12/2017	Please Select...	04/12/2017											
17/NW/0517	232120	Effectiveness and cost of integrating a protocol with use of liraglutide 3.0mg into an obesity service (STRIVE Study)	No		27			Within 70 Days		10/08/2017	25/10/2017	16/10/2017	14/11/2017	21/11/2017	Please Select...	21/11/2017											
15/LO/1681	185104	A double blind, randomized, placebo-controlled trial evaluating efficacy and safety of oral nintedanib, 150 mg twice daily for 52 weeks (with follow up until last patient out up to a maximum of 2 years) in patients with ?Systemic Sclerosis associated interstitial lung disease	No		18			No		30/03/2017	08/06/2017	07/06/2016	24/05/2017	26/06/2017	Please Select...	26/06/2017							Y				Neither
14/SC/1416	156215	A phase III multicentre randomised, double blind, placebo controlled trial to assess the role of intravenous immunoglobulin in the management of children with encephalitis (The IgNiTE study)	No					No		07/02/2017	13/06/2017	27/04/2016			Please Select...					Y							Sponsor
17/LO/1656	229212	A PHASE III, OPEN-LABEL, MULTICENTER, TWO ARM, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZOLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED BRAF WILD-TYPE MELANOMA	No					Within 70 Days		28/09/2017	20/11/2017	14/11/2017			Please Select...												
17/EM/0412	234907	An adaptive seamless randomized, double-blind, placebo-controlled, dose ranging study to investigate the efficacy and safety of LNP023 in primary IgA nephropathy patients	No					Within 70 Days		12/10/2017	08/12/2017	04/12/2017			Please Select...												
15/YH/0478	186697	A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis	No					Within 70 Days		27/04/2017	11/12/2017	26/04/2016			Please Select...												
17/LO/0035	218519	Development and evaluation of an intervention to support Adherence to treatment in adults with Cystic Fibrosis. A randomised controlled trial and parallel process evaluation.	No					Within 70 Days		20/01/2017	18/12/2017	03/04/2017			Please Select...												
17/SS/0052	196827	Early Valve Replacement guided by Biomarkers of Left Ventricular Decompensation in Asymptomatic Patients with Severe Aortic Stenosis	No					Within 70 Days		04/07/2017	20/12/2017	17/06/2017			Please Select...												